Overall BPMC gets a fundamental rating of 4 out of 10. We evaluated BPMC against 525 industry peers in the Biotechnology industry. BPMC has a bad profitability rating. Also its financial health evaluation is rather negative. BPMC shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year BPMC has reported negative net income.
BPMC had a negative operating cash flow in the past year.
BPMC had negative earnings in 4 of the past 5 years.
In the past 5 years BPMC reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -13.03%, BPMC belongs to the top of the industry, outperforming 82.55% of the companies in the same industry.
BPMC has a better Return On Equity (-45.52%) than 67.63% of its industry peers.

		Industry Rank	Sector Rank
ROA	-13.03%
ROE	-45.52%
ROIC	N/A

ROA(3y)-31.77%

ROA(5y)-25.69%

ROE(3y)-172.98%

ROE(5y)-112.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BPMC's Gross Margin of 96.48% is amongst the best of the industry. BPMC outperforms 96.22% of its industry peers.
In the last couple of years the Gross Margin of BPMC has grown nicely.
The Profit Margin and Operating Margin are not available for BPMC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.48%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.19%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BPMC has more shares outstanding
BPMC has more shares outstanding than it did 5 years ago.
BPMC has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 3.51 indicates that BPMC is not in any danger for bankruptcy at the moment.
BPMC's Altman-Z score of 3.51 is fine compared to the rest of the industry. BPMC outperforms 74.10% of its industry peers.
BPMC has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.01, BPMC is doing worse than 76.80% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	1.01
Debt/FCF	N/A
Altman-Z	3.51

ROIC/WACCN/A

WACC10.27%

2.3 Liquidity

A Current Ratio of 2.80 indicates that BPMC has no problem at all paying its short term obligations.
BPMC has a Current ratio of 2.80. This is in the lower half of the industry: BPMC underperforms 66.73% of its industry peers.
BPMC has a Quick Ratio of 2.75. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
BPMC has a worse Quick ratio (2.75) than 65.47% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.8
Quick Ratio	2.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.24% over the past year.
BPMC shows a strong growth in Revenue. In the last year, the Revenue has grown by 99.14%.
Measured over the past years, BPMC shows a very strong growth in Revenue. The Revenue has been growing by 50.23% on average per year.

EPS 1Y (TTM)57.24%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%43.94%

Revenue 1Y (TTM)99.14%

Revenue growth 3Y41.37%

Revenue growth 5Y50.23%

Sales Q2Q%55.45%

3.2 Future

BPMC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.63% yearly.
BPMC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.27% yearly.

EPS Next Y76.13%

EPS Next 2Y50.32%

EPS Next 3Y46.02%

EPS Next 5Y28.63%

Revenue Next Year41.72%

Revenue Next 2Y37.18%

Revenue Next 3Y32.66%

Revenue Next 5Y26.27%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BPMC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 131.18, which means the current valuation is very expensive for BPMC.
87.77% of the companies in the same industry are more expensive than BPMC, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 25.57, BPMC is valued quite expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	131.18

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as BPMC's earnings are expected to grow with 46.02% in the coming years.